Sales & Marketing News | pharmaphorum

News

FDA rejects Teva’s high-potency biosimilar of Humira again

Teva and partner Alvotech’s hopes of launching their biosimilar of AbbVie’s high-potency formulation of big-selling immunology drug Humira have been dashed, after the FDA

News

ICER backs sickle cell gene therapies at one-off cost of $2m

The influential Institute for Clinical and Economic Review (ICER) in the US has issued draft guidance suggesting that new gene therapies for sickle cell disease (SCD) from

News

Elizabeth Holmes heading for prison as appeal fails

Disgraced former biotech chief Elizabeth Holmes will start an 11-year prison sentence at the end of this month, after a federal judge denied her request to remain free whi

News

FDA advisors will look at full Leqembi approval in June

The FDA has convened a meeting of an advisory committee in June to consider the bid by Eisai and Biogen to convert their accelerated approval of Alzheimer’s disease therap

News

GSK told to pay higher royalties to AZ on Zejula sales

A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito

News

Pressure raises on Illumina as FTC orders it to shed Grail

The Federal Trade Commission has ordered Illumina to divest Grail, the cancer detection business it bought for $7.1 billion in 2021, saying it will “stifle” competition an

FDA rejects Teva’s high-potency biosimilar of Humira again

ICER backs sickle cell gene therapies at one-off cost of $2m

Elizabeth Holmes heading for prison as appeal fails

FDA advisors will look at full Leqembi approval in June

GSK told to pay higher royalties to AZ on Zejula sales

Pressure raises on Illumina as FTC orders it to shed Grail

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks